Vyome (NASDAQ:HIND) Stock Rating Lowered by Wall Street Zen

Vyome (NASDAQ:HIND) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

Vyome Trading Down 2.5%

Shares of HIND opened at $5.36 on Wednesday. Vyome has a twelve month low of $5.04 and a twelve month high of $720.00. The firm has a market capitalization of $3.59 million, a PE ratio of -0.01 and a beta of 1.05.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.